Credit: Arcutis. The approval was supported by data from 2 randomized, double-blind, vehicle-controlled trials that included 736 patients aged 12 years and older with mild to severe plaque psoriasis ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Roflumilast foam 0.3% is a formulation that can treat ...
Credit: Getty Images. Roflumilast foam is an investigational topical formulation of a highly potent and selective phosphodiesterase type 4 inhibitor. A phase 3 trial evaluating the efficacy and safety ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. By week 8, patients treated with roflumilast saw higher ...
A simple-to-use spray-on foam that quickly vanishes into the skin is the latest weapon in the battle against the debilitating skin condition psoriasis. Clinical trials into the newly licensed ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Once-daily roflumilast foam, 0.3% (Zoryve) significantly improved scalp and body symptoms of plaque psoriasis in a phase III trial. Improvements in scalp itch were also greater for patients randomized ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
The Food and Drug Administration (FDA) announced that it has accepted the supplemental New Drug Application (sNDA) for roflumilast foam 0.3% in adults and adolescents with scalp and body psoriasis ...
FDA Approves Topical Foam for Plaque Psoriasis of the Scalp and Body By Lori Solomon HealthDay ReporterTUESDAY, May 27, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved ...
Data from the INTEGUMENT trials demonstrates that ZORYVE cream 0.15% has a favorable safety profile and high tolerability, even among patients with prior inadequate responses to traditional treatments ...
Once-daily 0.3% topical roflumilast foam significantly reduced severity in patients with psoriasis of the scalp and body over 8 weeks, with a favorable safety profile. “Use of roflumilast foam was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results